263 related articles for article (PubMed ID: 27437940)
1. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
[TBL] [Abstract][Full Text] [Related]
3. N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence.
Wang Z; Liu Y; Takahashi M; Van Hook K; Kampa-Schittenhelm KM; Sheppard BC; Sears RC; Stork PJ; Lopez CD
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):312-7. PubMed ID: 23248303
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering.
Blaževitš O; Mideksa YG; Šolman M; Ligabue A; Ariotti N; Nakhaeizadeh H; Fansa EK; Papageorgiou AC; Wittinghofer A; Ahmadian MR; Abankwa D
Sci Rep; 2016 Apr; 6():24165. PubMed ID: 27087647
[TBL] [Abstract][Full Text] [Related]
5. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
[TBL] [Abstract][Full Text] [Related]
6. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract][Full Text] [Related]
7. Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner.
Posada IMD; Lectez B; Sharma M; Oetken-Lindholm C; Yetukuri L; Zhou Y; Aittokallio T; Abankwa D
Oncotarget; 2017 Jul; 8(27):44550-44566. PubMed ID: 28562352
[TBL] [Abstract][Full Text] [Related]
8. RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells.
Bjørndal B; Myklebust LM; Rosendal KR; Myromslien FD; Lorens JB; Nolan G; Bruland O; Lillehaug JR
Int J Cancer; 2007 Mar; 120(5):961-9. PubMed ID: 17149700
[TBL] [Abstract][Full Text] [Related]
9. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway.
Wu SZ; Xu HC; Wu XL; Liu P; Shi YC; Pang P; Deng L; Zhou GX; Chen XY
Phytomedicine; 2019 Jun; 59():152895. PubMed ID: 30913453
[TBL] [Abstract][Full Text] [Related]
10. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
11. Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation.
Šolman M; Ligabue A; Blaževitš O; Jaiswal A; Zhou Y; Liang H; Lectez B; Kopra K; Guzmán C; Härmä H; Hancock JF; Aittokallio T; Abankwa D
Elife; 2015 Aug; 4():e08905. PubMed ID: 26274561
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner.
Gault CR; Eblen ST; Neumann CA; Hannun YA; Obeid LM
J Biol Chem; 2012 Sep; 287(38):31794-803. PubMed ID: 22833671
[TBL] [Abstract][Full Text] [Related]
14. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of Raf kinase recruitment to the GTPase H-ras depends on H-ras membrane conformer-specific nanoclustering.
Guzmán C; Šolman M; Ligabue A; Blaževitš O; Andrade DM; Reymond L; Eggeling C; Abankwa D
J Biol Chem; 2014 Apr; 289(14):9519-33. PubMed ID: 24569991
[TBL] [Abstract][Full Text] [Related]
16. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.
Barradas M; Monjas A; Diaz-Meco MT; Serrano M; Moscat J
EMBO J; 1999 Nov; 18(22):6362-9. PubMed ID: 10562548
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.
Nakamura M; Kitaura J; Enomoto Y; Lu Y; Nishimura K; Isobe M; Ozaki K; Komeno Y; Nakahara F; Oki T; Kume H; Homma Y; Kitamura T
Cancer Sci; 2012 Jan; 103(1):26-33. PubMed ID: 21943131
[TBL] [Abstract][Full Text] [Related]
18. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3.
Shalom-Feuerstein R; Plowman SJ; Rotblat B; Ariotti N; Tian T; Hancock JF; Kloog Y
Cancer Res; 2008 Aug; 68(16):6608-16. PubMed ID: 18701484
[TBL] [Abstract][Full Text] [Related]
19. The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-α expression.
Robbs BK; Lucena PI; Viola JP
Biochim Biophys Acta; 2013 Aug; 1833(8):2016-28. PubMed ID: 23583303
[TBL] [Abstract][Full Text] [Related]
20. Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis.
Bigi A; Beltrami E; Trinei M; Stendardo M; Pelicci PG; Giorgio M
Oncogene; 2016 Sep; 35(39):5132-43. PubMed ID: 26973251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
